Fundraising FoxNovartis Venture Fund — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)Miquel Vila-Perelló, Ph.D(Co-Founder & CEO)Silvia Frutos, Ph.D(Co-Founder & CTO)
Co-investorsAsabys PartnersRoche Venture FundSanofi VenturesYsios CapitalCriteria Bio VenturesNew Enterprise Associates (NEA)+3 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatAnja Koenig· per SEC Form D
Co-investorsAgent CapitalGimvLongwood FundMission BiocapitalOno Venture Investment, Inc.Pfizer Venture Investments+5 more
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCBioGeneration VenturesEpidarex CapitalGlobal BioAccess FundUCL Technology Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.